Drugs / Buagafuran
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07457203 | Apr → May 2026 overdue | — | Beijing Union Pharmaceutical Factory Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07457190 | Mar → Aug 2026 overdue | generalized anxiety disorder | Beijing Union Pharmaceutical Factory Ltd | Not yet recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06243640 | Jul 2023 → Jun 2026 overdue | generalized anxiety disorder | Beijing Union Pharmaceutical Factory Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT06243614 | Jul 2023 → Jun 2026 overdue | generalized anxiety disorder | Beijing Union Pharmaceutical Factory Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Buagafuran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06243614 ↗ |
| Route | Oral | “Buagafuran, oral administration 30mg, signal dose in the morning of day1 and day5” NCT07457203 ↗ |